Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
oncolytic virus
Biotech
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
Replimune’s fortunes flipped today after an advisory committee voted 10 to 3 in favor of oncolytic virus RP1's effectiveness.
Darren Incorvaia
Jul 30, 2026 6:20pm
Boehringer bags viral vector platform for cancer vaccine R&D
Jul 7, 2026 10:35am
Replimune to lay off staff after 'disappointing' second rejection
Apr 10, 2026 1:56pm
Candel glows with $100M RTW deal to fund cancer drug launch
Feb 20, 2026 4:04am
Replimune's request for melanoma approval rejected by FDA
Jul 22, 2025 8:45am
Theriva prioritizes oncolytic adenovirus at expense of GvHD drug
Mar 7, 2025 4:47am
